Zenas BioPharma Soars on Encouraging Mid-Stage Trial Data, Meridian Fund Highlights Q4 Performance
U.S. equity markets delivered a complex performance in the final quarter of 2025, buoyed by hopes of monetary easing yet tempered by concerns over economic growth and stretched valuations. The Meridian Small Cap Growth Fund, managed by ArrowMark Partners, detailed this environment in its recently released Q4 2025 investor letter. While early quarterly gains were fueled by robust AI-sector earnings and an October rate cut from the Federal Reserve, momentum waned as the year drew to a close. Despite the moderation, small-cap stocks capped a strong year with a 12.8% annual return, though growth indices slightly trailed their value counterparts.
Amid this backdrop, clinical-stage biopharmaceutical company Zenas BioPharma (NASDAQ: ZBIO) emerged as a notable highlight for the fund. The company's shares surged approximately 30% in the month leading up to the letter's publication, culminating in a staggering 52-week gain of over 240%. By mid-February 2026, ZBIO closed at $26.68 per share, commanding a market value north of $1.4 billion. This remarkable rally is largely attributed to encouraging data from a Phase II trial for its lead autoimmune disease asset, which analysts suggest could address a significant unmet medical need and capture a multi-billion dollar market opportunity.
In its commentary, Meridian Fund noted Zenas BioPharma's progress while maintaining a measured outlook. "The recent clinical data from Zenas is undoubtedly promising and validates our initial thesis on the company's platform," the letter stated. However, it also pointed out that Zenas was not among the fund's list of the 30 most popular hedge fund holdings, with 13 funds holding the stock at the end of Q3 2025—a figure unchanged from the prior quarter. The fund's analysis suggests that while Zenas presents compelling potential, certain AI equities may currently offer a more favorable risk-reward profile for near-term gains.
Analyst & Investor Perspectives:
"Zenas is a textbook example of how binary event-driven biotech investing can pay off handsomely," says Dr. Anya Sharma, a biotech equity analyst at Veritas Capital. "The Phase II data de-risks the program considerably. The key now is watching enrollment for the pivotal Phase III study and monitoring the competitive landscape."
"The market is getting ahead of itself, as usual," argues Marcus Thorne, a portfolio manager known for his skeptical stance. "A successful Phase II does not guarantee regulatory approval or commercial success. At this valuation, you're pricing in perfection. Remember, this is a company with zero commercial revenue—it's all speculative."
"As a patient with the condition Zenas is targeting, this news brings real hope," shares Linda Chen, a patient advocate. "The existing treatments have significant limitations. Seeing a potential new therapy advance quickly through trials is the most tangible outcome we can ask for."
"From a portfolio construction view, Meridian's point is valid," adds David Reeves, a financial advisor. "For every Zenas, there are dozens of biotechs that fail. Diversifying across sectors, including AI, while maintaining a calculated position in high-conviction biotech names, is a prudent strategy for most growth-oriented investors."
The Meridian Small Cap Growth Fund reported a net return of 0.90% for Q4 2025, compared to a 1.22% return for the Russell 2000 Growth Index. The fund's full letter provides deeper insight into its top holdings and market outlook for the coming year.
Disclosure: This analysis is based on publicly available fund documents and market data. It is for informational purposes only and does not constitute investment advice.